Profile for Norway Patent: 2020004
✉ Email this page to a colleague
US Patent Family Members and Approved Drugs for Norway Patent: 2020004
| US Patent Number | US Expiration Date | US Applicant | US Tradename | Generic Name |
|---|---|---|---|---|
| ⤷ Start Trial | Oct 21, 2029 | Bayer Hlthcare | VITRAKVI | larotrectinib sulfate |
| ⤷ Start Trial | Oct 21, 2029 | Bayer Healthcare | VITRAKVI | larotrectinib sulfate |
| ⤷ Start Trial | Oct 21, 2029 | Bayer Hlthcare | VITRAKVI | larotrectinib sulfate |
| ⤷ Start Trial | Oct 21, 2029 | Bayer Healthcare | VITRAKVI | larotrectinib sulfate |
| >US Patent Number | >US Expiration Date | >US Applicant | >US Tradename | >Generic Name |
